Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.1K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

629
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
629
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

2.1K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.1K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

2.0K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansion.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Acute and longitudinal magnetic resonance imaging abnormalities in antibody-mediated encephalitis.

Brain communications·2026
Same author

Plasma proteome in LGI-1 autoimmune encephalitis.

Journal of neuroinflammation·2026
Same author

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Predicting disease progression in multiple sclerosis with clinically accessible information and technology.

Journal of neurology·2026
Same author

Corrigendum to "Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study" [Multiple Sclerosis and Related Disorders Vol 106; Feb 2026; Article Number 106885].

Multiple sclerosis and related disorders·2026
Same journal

Correction to: Recent Structural Insights into the Molecular Architecture of Synapses.

Advances in neurobiology·2026
Same journal

Roles of Glia in Synapse Nano-organization.

Advances in neurobiology·2026
Same journal

Visualizing Postsynaptic Density in Excitatory Synapses with Electron Tomography.

Advances in neurobiology·2026
Same journal

Optical Approaches to Dissect the Structure and Dynamics of the Synapse at Nanoscale Resolution.

Advances in neurobiology·2026
Same journal

Functional Nano-segregation of Distinct Forms of Neurotransmission.

Advances in neurobiology·2026
Same journal

Scales of Postsynaptic Nanostructure: Molecules, Nanoclusters, and Nanodomains.

Advances in neurobiology·2026
See all related articles

Related Experiment Video

Updated: Feb 27, 2026

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

5.3K

Multiple Sclerosis: Basic and Clinical.

Katherine Buzzard1, Wing Hei Chan2, Trevor Kilpatrick2,3,4

  • 1Department of Neurology, Royal Melbourne Hospital, Parkville, VIC, 3050, Australia.

Advances in Neurobiology
|July 5, 2017
PubMed
Summary
This summary is machine-generated.

Multiple sclerosis (MS) is a central nervous system disease causing nerve damage. Current treatments manage inflammation but don't repair myelin, highlighting the need for remyelination strategies.

Keywords:
DemyelinationMultiple sclerosisMyelinOligodendrocyteRemyelination

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.1K
Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

2.5K

Related Experiment Videos

Last Updated: Feb 27, 2026

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

5.3K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.1K
Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

2.5K

Area of Science:

  • Neuroscience
  • Immunology
  • Neurodegenerative Diseases

Background:

  • Multiple sclerosis (MS) is a leading neurodegenerative disease in young adults.
  • It involves immune-mediated damage to the central nervous system's myelin and axons.
  • Initial damage impairs nerve function, with a limited natural repair capacity.

Purpose of the Study:

  • To explore the mechanisms of myelin and oligodendrocyte influence on nerve cell health.
  • To identify therapeutic strategies beyond immune modulation for MS.
  • To address the critical challenge of remyelination in MS treatment.

Main Methods:

  • Review of current understanding of MS pathophysiology.
  • Analysis of existing therapeutic approaches and their limitations.
  • Identification of research gaps in remyelination and neural repair.

Main Results:

  • Immune therapies reduce relapses and new lesions but do not promote remyelination.
  • Oligodendrocytes and myelin play crucial roles in neuronal viability.
  • The capacity for endogenous repair diminishes over time, leading to degeneration.

Conclusions:

  • Effective MS treatment requires strategies that promote remyelination alongside immunomodulation.
  • Targeting remyelination is essential to combat the primary cause of disability in MS.
  • Future therapeutic efforts should focus on enhancing myelin repair and neural regeneration.